New Immunotherapeutic Agent for the Treatment of 5T4-positive Solid Tumors Shows Promise

Preclinical data for ALG.APV-527, a new immunotherapeutic candidate for the treatment of a variety of 5T4-positive solid tumors, being presented at the 33rd annual meeting of the Society for...

Phase II Trial Evaluating Lurbinectedin Shows Notable Efficacy in BRCA 1 and 2

Patients with BRCA1 or BRCA2-mutated metastatic breast cancer may benefit from treatment with lurbinectedin (PM1183 | Zepsyre®; PharmaMar), a selective inhibitor of active transcription of protein-coding genes. This is the...

Investigational Compound from Chinese Tree Bark Shows Potential as Treatment for Pancreatic Cancer

A new compound found in the bark of a rare Chinese tree, called FL118, has powerful anticancer properties and a low toxicity profile. This is what researchers at Roswell...

New Partnership Attacks Disparities in Cancer Outcomes

The National Cancer Institute (NCI) has awarded $2.17 million grant to develop a joint cancer drug discovery and development and research education program to focus on cancers that have...

Brentuximab Vedotin Included in New Supplemental BLA for Peripheral T-cell Lymphoma

Seattle Genetics has submitted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®) to the U.S. Food and Drug Administration (FDA). The submission is based on data from the...

Study Shows Promise in Preventing Heart Disease in Cancer Survivors

A study published in the Journal of Biological Chemistry by Washington State University researchers suggests that a protein called cyclin-dependent kinase 2 or CDK2 plays a critical role in...